The stock of Vera Therapeutics Inc (VERA) has gone up by 9.94% for the week, with a -9.49% drop in the past month and a -20.83% drop in the past quarter. The volatility ratio for the week is 7.48%, and the volatility levels for the past 30 days are 5.99% for VERA. The simple moving average for the past 20 days is 0.97% for VERA’s stock, with a -6.87% simple moving average for the past 200 days.
Is It Worth Investing in Vera Therapeutics Inc (NASDAQ: VERA) Right Now?
Moreover, the 36-month beta value for VERA is 1.11. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VERA is 48.99M and currently, short sellers hold a 14.88% of that float. On January 31, 2025, VERA’s average trading volume was 761.28K shares.
VERA) stock’s latest price update
The stock of Vera Therapeutics Inc (NASDAQ: VERA) has decreased by -1.19 when compared to last closing price of 37.93.Despite this, the company has seen a gain of 9.94% in its stock price over the last five trading days. globenewswire.com reported 2025-01-14 that BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 35,250 shares of Class A common stock and restricted stock units (RSUs) for 17,625 shares of Class A common stock to six new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Analysts’ Opinion of VERA
Many brokerage firms have already submitted their reports for VERA stocks, with Goldman repeating the rating for VERA by listing it as a “Buy.” The predicted price for VERA in the upcoming period, according to Goldman is $58 based on the research report published on January 28, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see VERA reach a price target of $70. The rating they have provided for VERA stocks is “Overweight” according to the report published on November 21st, 2024.
VERA Trading at -11.30% from the 50-Day Moving Average
After a stumble in the market that brought VERA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.38% of loss for the given period.
Volatility was left at 5.99%, however, over the last 30 days, the volatility rate increased by 7.48%, as shares sank -10.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.51% lower at present.
During the last 5 trading sessions, VERA rose by +9.94%, which changed the moving average for the period of 200-days by -21.87% in comparison to the 20-day moving average, which settled at $37.12. In addition, Vera Therapeutics Inc saw -11.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VERA starting from Fordyce Marshall, who sale 17,500 shares at the price of $41.74 back on Jan 08 ’25. After this action, Fordyce Marshall now owns 143,603 shares of Vera Therapeutics Inc, valued at $730,535 using the latest closing price.
MARSHALL FORDYCE, the Director of Vera Therapeutics Inc, proposed sale 17,500 shares at $42.10 during a trade that took place back on Jan 08 ’25, which means that MARSHALL FORDYCE is holding shares at $736,750 based on the most recent closing price.
Stock Fundamentals for VERA
The total capital return value is set at -0.42. Equity return is now at value -65.11, with -49.39 for asset returns.
Based on Vera Therapeutics Inc (VERA), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -2.2. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is -21.33.
Currently, EBITDA for the company is -102.01 million with net debt to EBITDA at -0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.60.
Conclusion
To wrap up, the performance of Vera Therapeutics Inc (VERA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
